195 related articles for article (PubMed ID: 30015608)
21. Characteristics of and meningococcal disease prevention strategies for commercially insured persons receiving eculizumab in the United States.
Bozio CH; Isenhour C; McNamara LA
PLoS One; 2020; 15(11):e0241989. PubMed ID: 33180804
[TBL] [Abstract][Full Text] [Related]
22. Meningococcal serogroup B vaccines: Estimating breadth of coverage.
Donald RG; Hawkins JC; Hao L; Liberator P; Jones TR; Harris SL; Perez JL; Eiden JJ; Jansen KU; Anderson AS
Hum Vaccin Immunother; 2017 Feb; 13(2):255-265. PubMed ID: 27960595
[TBL] [Abstract][Full Text] [Related]
23. Development and characterisation of outer membrane vesicle vaccines against serogroup A Neisseria meningitidis.
Norheim G; Aase A; Caugant DA; Høiby EA; Fritzsønn E; Tangen T; Kristiansen P; Heggelund U; Rosenqvist E
Vaccine; 2005 May; 23(29):3762-74. PubMed ID: 15893613
[TBL] [Abstract][Full Text] [Related]
24. Will booster doses be required for serogroup B meningococcal vaccine?
McQuaid F; Snape MD
Expert Rev Vaccines; 2014 Mar; 13(3):313-5. PubMed ID: 24451002
[TBL] [Abstract][Full Text] [Related]
25. Advances towards the prevention of meningococcal B disease: a multidimensional story.
Roderick M; Finn A
J Infect; 2014 Jan; 68 Suppl 1():S76-82. PubMed ID: 24139188
[TBL] [Abstract][Full Text] [Related]
26. Characterization of strains of Neisseria meningitidis causing meningococcal meningitis in Mozambique, 2014: Implications for vaccination against meningococcal meningitis.
Munguambe AM; de Almeida AECC; Nhantumbo AA; Come CE; Zimba TF; Paulo Langa J; de Filippis I; Gudo ES
PLoS One; 2018; 13(8):e0197390. PubMed ID: 30089105
[TBL] [Abstract][Full Text] [Related]
27. Meningococcal C conjugate vaccine effectiveness before and during an outbreak of invasive meningococcal disease due to Neisseria meningitidis serogroup C/cc11, Tuscany, Italy.
Pezzotti P; Miglietta A; Neri A; Fazio C; Vacca P; Voller F; Rezza G; Stefanelli P
Vaccine; 2018 Jul; 36(29):4222-4227. PubMed ID: 29895504
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of recombinant lipidated P2086 protein as a vaccine candidate for group B Neisseria meningitidis in a murine nasal challenge model.
Zhu D; Zhang Y; Barniak V; Bernfield L; Howell A; Zlotnick G
Infect Immun; 2005 Oct; 73(10):6838-45. PubMed ID: 16177362
[TBL] [Abstract][Full Text] [Related]
29. Fatal meningococcemia due to Neisseria meningitidis serogroup Y in a vaccinated child receiving eculizumab.
Polat M; Yüksel S; Şahin NÜ
Hum Vaccin Immunother; 2018; 14(11):2802. PubMed ID: 29883245
[No Abstract] [Full Text] [Related]
30. Investigation of serum bactericidal activity in childhood and adolescence 3-6 years after vaccination with a single dose of serogroup C meningococcal conjugate vaccine.
Sakou II; Tzanakaki G; Tsolia MN; Sioumala M; Barbouni A; Kyprianou M; Papaevangelou V; Tsitsika A; Blackwell CC; Kafetzis D; Kremastinou J
Vaccine; 2009 Jul; 27(33):4408-11. PubMed ID: 19500554
[TBL] [Abstract][Full Text] [Related]
31. The multicomponent meningococcal serogroup B vaccine (4CMenB): origin, composition, health impact and unknown aspects.
Mameli C; Galli E; Mantegazza C; Fabiano V; Zuccotti GV
Future Microbiol; 2015; 10(10):1579-98. PubMed ID: 26437903
[TBL] [Abstract][Full Text] [Related]
32. Antibiotic prophylaxis in vaccinated eculizumab recipients who developed meningococcal disease.
Crew PE; McNamara L; Waldron PE; McCulley L; Christopher Jones S; Bersoff-Matcha SJ
J Infect; 2020 Mar; 80(3):350-371. PubMed ID: 31783062
[No Abstract] [Full Text] [Related]
33. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants.
Morley SL; Cole MJ; Ison CA; Camaraza MA; Sotolongo F; Anwar N; Cuevas I; Carbonero M; Campa HC; Sierra G; Levin M
Pediatr Infect Dis J; 2001 Nov; 20(11):1054-61. PubMed ID: 11734711
[TBL] [Abstract][Full Text] [Related]
34. Toward a meningitis-free world.
Black S; Pizza M; Nissum M; Rappuoli R
Sci Transl Med; 2012 Feb; 4(123):123ps5. PubMed ID: 22378923
[TBL] [Abstract][Full Text] [Related]
35. The Changing Epidemiology of Meningococcal Disease.
Cohn A; MacNeil J
Infect Dis Clin North Am; 2015 Dec; 29(4):667-77. PubMed ID: 26610420
[TBL] [Abstract][Full Text] [Related]
36. [With paroxysmal nocturnal haemoglobinuria and treatment with eculizumab].
Algado JT; Luque R; Nuñez R; Sanchez B
Enferm Infecc Microbiol Clin; 2012 Feb; 30(2):109-10. PubMed ID: 22197277
[No Abstract] [Full Text] [Related]
37. Exploring the population-level impact of MenB vaccination via modeling: Potential for serogroup replacement.
Hogea C; Van Effelterre T; Vyse A
Hum Vaccin Immunother; 2016; 12(2):451-66. PubMed ID: 26308796
[TBL] [Abstract][Full Text] [Related]
38. [Paediatric meningococcal meningitis in France: ACTIV/GPIP network results].
Levy C; Taha MK; Bingen E; Cohen R;
Arch Pediatr; 2012 Sep; 19 Suppl 2():S49-54. PubMed ID: 22883366
[TBL] [Abstract][Full Text] [Related]
39. Background Paper for the update of meningococcal vaccination recommendations in Germany: use of the serogroup B vaccine in persons at increased risk for meningococcal disease.
Hellenbrand W; Koch J; Harder T; Bogdan C; Heininger U; Tenenbaum T; Terhardt M; Vogel U; Wichmann O; von Kries R
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2015 Nov; 58(11-12):1314-43. PubMed ID: 26487381
[TBL] [Abstract][Full Text] [Related]
40. Challenges for development of meningococcal vaccines in infants and children.
Deasy A; Read RC
Expert Rev Vaccines; 2011 Mar; 10(3):335-43. PubMed ID: 21434801
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
